Begin Main Content Area

Announcements

To be added to DDAP's listserv and receive updates from the department, please email RA-DAPressOffice@pa.gov with your name(s), organization, and email address(es). Please include "Listserv" in the subject line.


  
  
Body
4/7/2021 3:42 PMGrant Initiative Funding Opportunity

​The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is pleased to announce a new Grant Initiative Funding Opportunity.

GIFA 21-01 – Recovery Community Support Services
DDAP is accepting applications for Recovery Community Organizations (RCOs) who will expand or enhance recovery support services to individuals in recovery from SUD. Such services include the delivery of recovery coaching through Certified Recovery Specialists (CRS), telephonic supports, the provision of education and employment supports, e.g. job coaching, resume writing, engagement in GED services, additional life-skills support groups and delivery of substance-free social activities, etc. It is the expectation that such RCOs embrace individuals seeking services regardless of their recovery pathway.  Applications are due Monday May 3, 2021 by 12 PM.

3/24/2021 9:10 AMPA Unite Against COVID

​We know there’s a lot of information out there about COVID vaccines, and it can be hard to keep track of it all. That’s why we created the Unite Against COVID Weekly Update. Subscribe to get a round-up of news you can use and answers to your most pressing vaccine questions – delivered directly to your inbox every week. When you have good information, you can make good decisions.

The rollout of COVID-19 vaccine gives us hope, and a path back to our lives. Learn more at pa.gov/covid.

3/19/2021 8:02 AMDeadline Extension - MDAIR Member Application Survey

DDAP Seeking MDAIR Team Members
The Department of Drug and Alcohol Programs (DDAP) is seeking members for the Medication Death and Incident Review (MDAIR) Team. This team will review circumstances surrounding medication-related deaths and incidents for medications approved by the FDA for the treatment of opioid use disorder. These reviews will lead to recommendations that promote safety, reduce deaths and incidents, as well as improve treatment.  

DDAP is excited about the overwhelming amount of interest so far. If you’re interested in applying, we have received a limited number of applications from the fields in red:

  • narcotic treatment programs
  • licensed drug and alcohol treatment providers
  • law enforcement
  • the medical community
  • district attorneys
  • coroners and medical examiners
  • community members
  • individuals with a substance use disorder or family advocates
  • individuals from recovery organizations
  • individuals that prescribe buprenorphine with a DEA number related to prescribing
  • toxicologists

The deadline to apply has been extended to March 26, 2021. DDAP will continue to welcome applications from all of the above categories until that time. If you are interested in sharing your knowledge, positively affecting the drug and alcohol treatment system, and can dedicate approximately 30 hours per year, please complete the application via SurveyMonkey. Please pass this message along to other individuals who may be interested in applying.

DDAP will review applications and select members within 3 weeks of the application closing date. Questions can be submitted to Derrick Pelletier at dpelletier@pa.gov.

3/8/2021 9:26 AMDDAP Seeking Medication Death and Incident Review Team Members

The Department of Drug and Alcohol Programs (DDAP) is seeking members for the Medication Death and Incident Review (MDAIR) Team. This team will review circumstances surrounding medication-related deaths and incidents for medications approved by the FDA for the treatment of opioid use disorder. These reviews will lead to recommendations that promote safety, reduce deaths and incidents, as well as improve treatment. The MDAIR Team is established by Act 126 of 2020.

DDAP is seeking representation from:

  • narcotic treatment programs
  • licensed drug and alcohol treatment providers
  • law enforcement
  • the medical community
  • district attorneys
  • coroners and medical examiners
  • community members
  • individuals with a substance use disorder or family advocates
  • individuals from recovery organizations
  • individuals that prescribe buprenorphine with a DEA number related to prescribing
  • toxicologists

If you are interested in sharing your knowledge, positively affecting the drug and alcohol treatment system, and can dedicate approximately 30 hours per year, please complete the application via SurveyMonkey by March 19, 2021.
 
DDAP will review applications and select members within 3 weeks of the application closing date. Questions can be submitted to Derrick Pelletier at dpelletier@pa.gov.​

3/4/2021 3:31 PMProblem Gambling Awareness Month Kickoff

​The 2021 Problem Gambling Awareness Month Kickoff recording is now available.
Watch: https://ddap.webex.com/ddap/ldr.php?RCID=fe818e74df2e4ce587d93cef47cc94db
Password: 8xJTCw3p

2/25/2021 10:52 AMDDAP Prevention Manual Modifications

​The Department of Drug and Alcohol Programs has released Policy Bulletin 21-01 which documents modifications made to the DDAP Prevention Manual relating to DDAP-funded paid advertisements.

Policy Bulletin 21-01 and the updated 2020-2025 Prevention Manual can be found on the DDAP website.


2/19/2021 1:52 PMFebruary COVID-19 Update

Rite Aid Pharmacy Partnership with Residential Drug and Alcohol Treatment Providers
The Pennsylvania Departments of Human Services, Health, and Drug and Alcohol Programs have established a partnership with Rite Aid to ensure providers of congregate care settings throughout the commonwealth have access to the COVID-19 vaccine. The partnership is a result of a survey sent to DDAP residential treatment providers on January 26, 2021, to better understand how many providers were still in need of establishing a partnership with a vaccine provider in Pennsylvania.
 
If you are a residential treatment provider still in need of establishing a partnership, please let us know by contacting DDAP’s Dan Miller at ddap-eplo@pa.gov.  If your facility meets the qualifications to participate in this partnership, we will connect you with a Rite Aid location who can come to your residential facility to vaccinate your residents and staff. To identify a vaccine provider in your local area, visit https://www.health.pa.gov/topics/disease/coronavirus/Vaccine/Pages/Vaccine.aspx.

Your Turn Eligibility Tool
If you or your staff are unsure if you qualify to receive a COVID-19 vaccine during phase 1a of Pennsylvania’s vaccine distribution plan, the Wolf Administration’s recently released the Your Turn tool to identify eligibility and provide notifications when you, or a loved one, are eligible for vaccinations. To access the tool, visit https://covidportal.health.pa.gov/s/Your-Turn.
 
Vaccine Supply Remains Limited
It is important to note that the vaccine supply is still very limited throughout the commonwealth and we ask for your patience as more vaccine becomes available. For the most up to date information on the COVID-19 vaccine and Pennsylvania’s vaccine distribution plan, visit the Department of Health’s website www.health.pa.gov.

2/8/2021 2:35 PMSAMHSA’s New Series of Advisories on Substance Use Disorder Treatment

SAMHSA has published a series of Advisories based on existing Treatment Improvement Protocols (TIPs) and Technical Assistance Publications (TAPs). These Advisories summarize updated guidance and recommendations on topics in the substance use disorder (SUD) treatment field. The new Advisories are listed below and links to each can be found here.

Advisory: Comprehensive Case Management for Substance Use Disorder Treatment
Published: January 2021
This Advisory is based on TIP 27, Comprehensive Case Management for Substance Abuse Treatment. It surveys the underlying principles and models of case management, discusses reasons SUD treatment providers might consider implementing or expanding the use of case management, and lists some case management resources and tools.

Advisory: Using Motivational Interviewing in Substance Use Disorder Treatment
Published: January 2021
This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in SUD treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

Advisory: Screening and Treatment of Viral Hepatitis in People With Substance Use Disorders
Published: January 2021
This Advisory is based on TIP 53, Addressing Viral Hepatitis in People With Substance Use Disorders. It offers guidance to providers and administrators in SUD treatment programs on screening for, and treating clients with, hepatitis A, hepatitis B, and hepatitis C infections.

Advisory: Screening and Treatment of Substance Use Disorders Among Adolescents
Published: January 2021
This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders and TIP 32, Treatment of Adolescents With Substance Use Disorders. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.

Advisory: Addressing Suicidal Thoughts and Behaviors in Substance Use Treatment
Published: January 2021
This Advisory is based on TIP 50, Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment. It provides strategies for identifying and addressing suicidal thoughts and behaviors among individuals with SUDs.

Advisory: Treating Substance Use Disorders Among People With HIV
Published: January 2021
This Advisory is based on TIP 37, Substance Abuse Treatment for Persons With HIV/AIDS. It highlights strategies and considerations for SUD treatment providers to effectively engage people with HIV in SUD treatment.

Advisory: Group Therapy in Substance Use Treatment
Published: January 2021
Based on TIP 41, Substance Abuse Treatment: Group Therapy, this Advisory provides an overview of goals, processes, group-specific approaches, resources, and common elements that support favorable outcomes in group therapy.

Advisory: Prescribing Pharmacotherapies for Patients With Alcohol Use Disorder
Published: January 2021
This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for alcohol use disorder (AUD), and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

Advisory: The Importance of Family Therapy in Substance Use Disorder Treatment
Published: January 2021
This Advisory is based on TIP 39, Substance Use Disorder Treatment and Family Therapy. It surveys basic factors for programs and providers to consider when implementing family-related therapy approaches, goals and processes for conducting effective family counseling, and resources for further learning about family therapy techniques and models.

Advisory: The Substance Use Disorder Counseling Competency Framework: An Overview
Published: January 2021
This Advisory is based on TAP 21, Addiction Counseling Competencies: The Knowledge, Skills, and Attitudes of Professional Practice. It discusses the development of the counseling competencies and the validated research on which they are based, provides a simplified overview of their structure and the elements of a typical competency, and outlines how these competencies are changing the field of SUD treatment nationwide. The Advisory also addresses the critical role of cultural competence.

Advisory: Integrating Vocational Services into Substance Use Disorder Treatment
Published: January 2021
This Advisory, based on TIP 38, Integrating Substance Abuse Treatment and Vocational Services, presents strategies and resources for SUD treatment counselors and program directors to improve outcomes for clients in recovery by helping them find and keep employment and deal with workplace stresses. This Advisory is directed to programs serving clients who are unemployed, underemployed, or struggling in workplace settings.

1/25/2021 11:02 AMFree home HIV test kits

​The Pennsylvania Department of Health, in partnership with the Pennsylvania Expanded HIV Testing Initiative (PEHTI) and the HIV Prevention and Care Project (HPCP), has introduced HIV Self-Testing (HST) for individuals who reside in Pennsylvania (excluding Philadelphia County). The goal of the getmyHIVtest.com program is to help people get tested who wouldn’t otherwise go to their doctor or to a testing clinic.  

Tests are available from the website getmyhivtest.com. Individuals are asked to read the information on the website and answer a few questions in order to receive an FDA-approved, OraQuick home HIV test kit mailed to the address they provide. Support for clients who request and administer the HIV self-test is available through OraQuick and the HPCP, as noted on the website.   

Individuals who reside in Philadelphia County should visit PhillyKeepOnLoving.com to order the HIV Self-test kit and for additional information about testing from the Philadelphia Department of Public Health.   

If you have any questions, please send an email to info@getmyHIVtest.com.

1/14/2021 9:48 AMJanuary COVID-19 Vaccine Update

​Hello DDAP Stakeholders,

I hope you are well, safe, and healthy as we start the new year.

I would like to share updates on the commonwealth’s COVID-19 vaccination process, as well as provide tips on how you can prepare your organizations to receive vaccine.

Vaccination Process
Last Friday, the Department of Health (DOH) released the fourth version of its COVID-19 Interim Vaccination Plan. The plan is both fluid and flexible to meet the latest federal guidance and recommendations. It will continue to receive updates. DOH released this version with a Feedback Form that invites public comment on the plan. This feedback will help inform Pennsylvania’s  vaccination planning.

Pennsylvania continues to work its way through the initial phase of vaccine distribution – Phase 1A. This phase is focused on frontline, healthcare personnel, emergency medical first responders, and long-term care facility residents. The time it will take to complete this phase is influenced by factors like:

  • the limited amount of available vaccine,
  • which vaccines are available,
  • the storage capabilities of private/public partners, and
  • Pennsylvania’s allocation from the federal government.

Many of DDAP’s stakeholders will be in the next phase of vaccinations, Phase 1B. While the above factors make it difficult to determine when or where that phase will start, there are several things you can do to prepare your organizations.

How to Prepare
Identify one nearby hospital or healthcare system enrolled to provide COVID-19 vaccine.

  • Monday, the Department of Health launched its Pennsylvania Vaccine Provider Map. This map shows all entities that are enrolled to provide vaccine. Using this map, you should identify a nearby location where your staff can get vaccine at the appropriate time.
  • The Map identifies contact information for the specific location’s vaccine liaison. Connect with the individual to ensure you have all necessary information to prepare your staff.

Prioritize Staff

  • Due to vaccine availability, your entire staff might not be able to receive vaccine at the same time. Be prepared to prioritize those staff that are at greatest risk for exposure.
  • Encourage staff to visit their primary care physicians to review their medical history, ensuring they are eligible for vaccination.

Prepare Necessary Documentation for Staff

  • Staff will have to provide proof of occupation to receive vaccine. This could include a state license or certification, letter from employer on organization letterhead, facility identification/security badge or other proof of occupation. Ensure that these documents are ready.

Stay Informed

  • For the most up-to-date information on Pennsylvania’s vaccine distribution, I encourage each of you to regularly visit the Department of Health’s COVID-19 vaccine portion of their website, as well as their news section which provides updates to how much vaccine and where vaccine was received in Pennsylvania.  Feel free to utilize the COVID-19 vaccine toolkit which provides vaccine development background, facts, and graphics for your facilities and social media channels.

DDAP’s Commitment
DDAP’s commitment to each of you is to be transparent throughout the vaccine planning process. We are working closely with the Department of Health to provide information to you as quickly as possible, but I ask for your continued patience as the logistics are developed and finalized.

Thank you for your continued patience as more information becomes available and for your continued partnership in ensuring all members of Pennsylvania’s drug and alcohol system remains safe.

Questions can be forwarded to Derrick Pelletier at dpelletier@pa.gov.

Be well,
Jen Smith
DDAP Secretary

1/7/2021 9:29 AMUpdated ASAM document available

​DDAP has replaced the Addendum PA-Specific Alignment Requirements 2.0 (IOP/PHP) document that was previously posted to our website. The revised document specifically focuses on items related to Partial Hospitalization Program requirements that had not been fully identified in the prior edition.

12/22/2020 9:31 AMMessage from Secretary Smith

​Thank you for your continued dedication to the health and safety of Pennsylvanians, we could not do what we do without you. Happy holidays from all of us at DDAP.

WATCH VIDEO

Screenshot_2020-12-16 SecretaryMessage4 mp4.jpg

12/18/2020 8:46 AM2019-20 Women and Children's Annual Report

​We are pleased to announce the 2019-20 Women and Children’s Annual Report is available on the DDAP website.

12/16/2020 12:20 PMCOVID-19 vaccine update

​Good afternoon DDAP stakeholders,

I hope this message finds you and your loved ones well during this unique holiday season. I wanted to take the opportunity to address a very anticipated and historic aspect of supporting Pennsylvanians through the pandemic – the much awaited arrival of the first COVID-19 vaccines.

As I am sure you are aware, the commonwealth received it’s first allotment of COVID-19 from Pfizer on Monday of this week. As detailed in the Department of Health’s interim vaccine distribution plan, the first priority group to be vaccinated are our Pennsylvania hospital workers who are directly caring for COVID-19 patients. As more vaccine becomes available, the Department of Health will continue to ensure that distribution of the vaccine arrives at the designated, enrolled hospital and health care systems throughout the commonwealth or established vaccine distribution partner to administer vaccinations to the groups identified in the current distribution plan.

I want to take a moment to reiterate two very important aspects of the vaccine distribution:

  1. At this time there is a very limited supply to meet the demand of Pennsylvanians currently eligible for the vaccine. However, myself and the entire Wolf Administration want to assure each of you, your staff and coworkers, and loved ones that all Pennsylvanians who would like to be vaccinated will have access to vaccine. This is simply the first step in a vaccination process that will take months to complete.
  2. If you have taken the time to review the plan, you will see that there are still many details to be finalized and subgroups to be identified. The Department of Health has stated that the interim plan is very much a working document and will continue to be updated as the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices identifies further priority populations. At this time, drug and alcohol treatment providers are referenced in the plan as eligible for vaccinations during phase 1b. It is also important to recognize that the “vaccination phases” will happen at their own pace throughout the commonwealth. For example, if vaccine distributors in the western part of the commonwealth vaccinate Pennsylvanians quicker than the central area, they will move through priority populations and “phases” more rapidly.


At this time vaccination distribution planning remains very fluid due to key aspects of planning and preparation still outstanding, i.e. the amount of vaccine available to Pennsylvanians, which vaccine will be available, what private/public partners have the storage capabilities and sheer manpower to host a vaccine distribution site.

I write today to express the Department of Drug and Alcohol Programs’ commitment to each of you in being transparent throughout the vaccine planning process including but not limited to:

  • when treatment providers will be eligible for vaccinations,
  • how providers will receive notifications of vaccine availability, and
  • where individuals need to present to access their vaccination, etc.


We are working closely with the Department of Health to provide information to you as quickly as possible, but I ask for your continued patience as the logistics are developed and finalized.

For the most up-to-date information on Pennsylvania’s vaccine distribution, I encourage each of you to regularly visit the Department of Health’s COVID-19 vaccine portion of their website, as well as their news section which provides updates to how much vaccine and where vaccine was received in Pennsylvania.  Feel free to utilize the COVID-19 vaccine toolkit which provides vaccine development background, facts, and graphics for your facilities and social media channels.

Thank you for your continued patience as more information becomes available and for your continued partnership in ensuring all members of Pennsylvania’s drug and alcohol system remains safe.

Be well,

Jen Smith
DDAP Secretary

12/14/2020 10:00 AMNew ASAM Alignment FAQ Available

​We are pleased to announce that the FAQ document for ASAM Alignment of Level 2.0 Intensive Outpatient and Partial Hospitalization Services has been posted to the DDAP website.

12/1/2020 9:40 AM​2020 Compulsive and Problem Gambling Annual Report

DDAP is pleased to release the 2020 Compulsive and Problem Gambling Annual Report.

This report details the impact of programs funded by the Compulsive and Problem Gambling Treatment Fund including SCA funding, gambling treatment provider funding, and oversight of programs, trainings, and helpline services.

11/9/2020 1:32 PMSABG Public Review/Comment Notice

​The Department of Drug and Alcohol Programs is providing the opportunity for public comment on the Pennsylvania Substance Abuse Prevention and Treatment Block Grant (SABG) Submission. This submission occurs in three parts: The Substance Abuse Prevention and Treatment Assessment and Plan which was submitted to SAMHSA on October 1, 2019, the SABG Report which is currently in process and will be submitted by December 1, 2020, and the Annual Synar Report which will be made available for review in December and submitted to SAMHSA by December 31, 2020.

These documents can be accessed at https://bgas.samhsa.gov/Module/BGAS/Users utilizing “citizenpa” as your login and “citizen” as your password.

Please submit all comments to ra-dabaps@pa.gov by November 27, 2020 for the SABG Report and by December 28, 2020 for the Synar Report.

11/9/2020 10:31 AMASAM Alignment Resources Available

​New resources are available for the 2.0 Intensive Outpatient and Partial Hospital Programs ASAM Criteria Service Alignment on the DDAP website.


11/5/2020 3:40 PMPsychostimulant Symposium - Registration is Open!

​We are pleased to announce that registration is open for the virtual Pennsylvania Psychostimulant Symposium.

Dates: December 2-3, 2020.

Format: This is a one and one-half-day virtual event featuring plenary and breakout sessions.

Overview: Both public health and public safety professionals require additional training and information to better respond to psychostimulant overdose victims, and treatment professionals require additional tools to effectively treat patients who misuse or abuse psychostimulants. Strategies essential for detecting surges in psychostimulant supply and consumption can aid policymakers and agency leaders in directing resources where most needed.

Target Audience: Law enforcement, criminal justice, health care providers, emergency medical services personnel, drug and alcohol prevention and treatment providers, Single County Authorities (SCAs), government officials, public health professionals, and other interested stakeholders.

Registration: Attendance is free, but registration is required and limited. Register online by clicking here. After you register with Adobe at the link provided, you’ll receive another email to register separately for the breakout sessions. PLEASE NOTE, if you have not already attended a DDAP Adobe event, your registration will include establishing an account by creating a password.

More Information: Please visit our webpage for details about agenda, continuing education credits, session descriptions.

Questions regarding these summits may be emailed to ra-daPAPSSymposium@pa.gov.

10/8/2020 9:41 AMASAM Alignment Resources Available

​We are pleased to announce the availability of new ASAM Alignment resources on the DDAP website.  

  • Level 4.0 Medically Managed Intensive Inpatient PowerPoint slides  
  • Level 4.0 Medically Managed Intensive Inpatient recorded presentation

10/8/2020 9:16 AMASAM IOP/PHP Rollout Presentations Have Been Rescheduled

​The IOP/PHP Rollout Sessions have been rescheduled for the first week of November. Providers should visit our website for specific dates, times, links and call-in details to join the meeting. Participants are highly encouraged to engage in the webinar by Skype rather than by phone in order to access the video portion of the presentation. Detailed information will be shared by video that will be advantageous to participants.

10/8/2020 9:15 AMCMS reminds States of mandatory Medicaid MAT coverage starting October 1st

​CMS reminds states of the SUPPORT Act Medicaid Medication Assisted Treatment (MAT) services and drugs mandatory coverage starting October 1st

CMS wants to remind states that effective October 1, 2020, state Medicaid programs are required to provide coverage of Medication Assisted Treatment (MAT) services and drugs under a new mandatory benefit. The SUPPORT Act of 2018 (P.L. 115-271) amended the Social Security Act (the Act) to add this new mandatory benefit.  The purpose of the new mandatory MAT benefit found at section 1905(a)(29) of the Act is to increase access to evidenced-based treatment for Opioid Use Disorder (OUD) for all Medicaid beneficiaries and to allow patients to seek the best course of treatment and particular medications that may not have been previously covered.

CMS interprets sections 1905(a)(29) and 1905(ee) of the Act to require that, as of October 1, 2020, states must include as part of the new MAT mandatory benefit all forms of drugs and biologicals that the Food and Drug Administration (FDA) has approved or licensed for MAT to treat OUD.  More specifically, under the new mandatory MAT benefit, states are required to cover such FDA approved or licensed drugs and biologicals used for indications for MAT to treat OUD.  States currently cover many of these MAT drugs and biologicals (for all medically-accepted indications) under the optional benefit for prescribed drugs described at section 1905(a)(12) of the Act.

The President has signed H.R. 8337, the Continuing Appropriations Act, 2021 and Other Extensions Act. This new law made a statutory change to Section 1905(a)(29) and 1905(ee) of the Act, and now clarifies that MAT drugs when used for OUD as described under the mandatory benefit are deemed prescribed drugs, and covered outpatient drugs subject to section 1927 of the Act requirements, as appropriate.

Specifically, these amendments to the Act ensure a state’s ability to seek section 1927 drug manufacturer rebates, and apply drug utilization management mechanisms, such as preferred drug lists and prior approval, and a manufacturer’s duty to pay appropriate rebates and comply with all applicable manufacturer drug product and drug pricing reporting and payment of rebates. The change in law is effective as of the date of enactment of the original SUPPORT Act, which was October 24, 2018. Further CMS guidance will be forthcoming on other implementation issues relating to this new mandatory MAT benefit.

View in web browser: https://content.govdelivery.com/accounts/USCMSMEDICAID/bulletins/2a3b044

10/8/2020 9:14 AMNew ASAM Alignment Documents Available

DDAP is pleased to announce documents for ASAM Alignment of Level 4 Medically Managed Intensive Inpatient have been posted to our website.

  • Level 4 by Service Characteristics
  • Level 4 Self-Assessment
  • Addendum: PA-Specific Alignment Requirements - Level 4

10/5/2020 12:45 PMDDAP Funding Opportunities

GIFA 20-05 Pregnancy Support Service
DDAP is accepting applications for providers who will provide pregnancy support services or make referrals to address the needs of pregnant and postpartum women with stimulant or opioid misuse issues. In addition, these community providers will facilitate or make referrals for outpatient Medication-Assisted Treatment (MAT) and stimulant misuse treatment.

Applications shall be submitted via email to RA-DAGrantsMgmt@pa.gov through Friday, October 30, 2020 by 12:00 PM.



FIA 20-04 Police Diversion to Treatment
DDAP is accepting applications from SCAs who shall expand or create a collaborative between local law enforcement, treatment professionals and recovery support providers to establish a diversion program. Active and engaged relationships with the local District Attorney, identified local police departments, Opioid Use Disorder (OUD) treatment providers, Stimulant Use Disorder treatment providers, and Certified Recovery Specialists (CRS) shall be foundational to such an initiative. Rather than experiencing legal consequences from stimulant or opioid misuse issues, individuals shall receive treatment and support services for the underlying cause of the arrest.

Applications shall be submitted via email to RA-DAGrantsMgmt@pa.gov  through Friday, October 23, 2020 by 12:00 PM.


For more information about funding opportunities visit our website.

9/3/2020 1:44 PMNew Data on School Safety, Substance Use, Mental Health

​Do students who feel safer at school use substances less and report less symptoms of depression?  

DDAP’s State Epidemiological Outcomes Workgroup (SEOW) looked at data from the 2019 PA Youth Survey (PAYS) to help answer this question. The SEOW developed a short report to highlight some of the PAYS data related to school safety, substance use, and mental health. According to the 2019 PAYS, feelings of safety at school among high school students are associated with decreased odds of substance use, symptoms of depression, and suicidal ideation. This data continues to emphasize the importance of efforts to focus on a positive school climate with a focus on safety, support, and social-emotional learning to provide equitable learning environments for PA youth.

9/2/2020 8:30 AMNew ASAM Alignment FAQ Available

​DDAP is pleased to announce that the FAQ document for ASAM Alignment of Level 1.0 Outpatient Services has been posted to our website.

8/25/2020 12:24 PMDDAP Recovery Month Event Calendar

​Is your organization hosting an event during the month of September in honor of National Recovery Month? We’re gathering a list of statewide events to promote on our 2020 National Recovery Month webpage.

If you would like your event to show on our calendar, please email the DDAP Press Office.

8/20/2020 11:02 AMNew ASAM documents available
8/19/2020 8:32 AMSABG Public Comment

​The Department of Drug and Alcohol Programs is providing the opportunity for public comment on its annual Pennsylvania Substance Abuse Prevention and Treatment Block Grant (SABG) Submission. This submission will occur in three parts:

  1. The Substance Abuse Prevention and Treatment (SAPT) Plan which will be submitted to SAMHSA by October 1 and is currently available in draft and available for review by September 30;
  2. The SAPT Report which will be available in November for comment prior to submission on December 1st, and;
  3. The Annual Synar Report which will also be made available in December for comment prior to submission on December 31st.

These documents can be accessed at https://bgas.samhsa.gov utilizing “citizenpa” as your login and “citizen” as your password.

Please submit all comments to ra-dabaps@pa.gov by timeframes indicated.

8/18/2020 9:29 AMSUD Confidentiality Survey

​As a reminder, a Pennsylvania Department of Drug and Alcohol Programs (DDAP) survey seeking stakeholder feedback on Pennsylvania's Substance Use Disorder (SUD) confidentiality regulations will be open for two more weeks. Please let us know how these requirements are working and if they can be improved before this survey closes on August 31st!

Share your input here:
https://www.surveymonkey.com/r/Confidentiality_Practices

Over 1,200 people have already completed this survey. Thank you to everyone who has taken time to share insight on this important subject. Your feedback is greatly appreciated. Please share this message with colleagues and partners who have an interest in this subject.

You can find more information about this project, as well as information on current SUD confidentiality requirements, on the DDAP website.

1 - 30Next